Efficacy of Extended-Release Injectable Naltrexone on Alcohol Use Disorder Treatment: A Systematic Review

References

• Aletraris, L., M. B. Edmond, and P. M. Roman. 2015. Adoption of injectable Naltrexone in U.S. substance use disorder treatment programs. Journal of Studies on Alcohol and Drugs 76 (1):143–51. doi:10.15288/jsad.2015.76.143.
   PubMed Web of Science ®Google Scholar
• Bouza, C., M. Angeles, A. Magro, A. Muñoz, and J. M. Amate. 2004. Efficacy and safety of naltrexone and Acamprosate in the treatment of alcohol dependence: A systematic review. Addiction (Abingdon, England) 99 (7):811–28. doi:10.1111/j.1360-0443.2004.00763.x.
   PubMed Web of Science ®Google Scholar
• Busch, A. C., M. Denduluri, J. Glass, S. Hetzel, S. P. Gugnani, M. Gassman, D. Krahn, B. Deyo, and R. Brown. 2017. Predischarge injectable versus oral naltrexone to improve postdischarge treatment engagement among hospitalized veterans with alcohol use disorder: A randomized pilot proof-of-concept study. Alcoholism, Clinical and Experimental Research 41 (7):1352–60. doi:10.1111/acer.13410.
   PubMed Web of Science ®Google Scholar
• Canidate, S. S., G. D. Carnaby, C. L. Cook, and R. L. Cook. 2017. A systematic review of naltrexone for attenuating alcohol consumption in women with alcohol use disorders. Alcoholism, Clinical and Experimental Research 41 (3):466–72. doi:10.1111/acer.13313.
   PubMed Web of Science ®Google Scholar
• CDC. (2016). Impaired driving: Get the facts | Motor vehicle safety | CDC injury center. https://www.cdc.gov/motorvehiclesafety/impaired_driving/impaired-drv_factsheet.html (Accessed October 08, 2019).
   Google Scholar
• Centers for Disease Control and Prevention. (2018, September 20). Fact sheets-alcohol use and health—Alcohol. https://www.cdc.gov/alcohol/fact-sheets/alcohol-use.htm
   Google Scholar
• Cisler, R. A., B. L. Silverman, I. Gromov, and D. R. Gastfriend. 2010. Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence. Journal of Addiction Medicine 4 (3):181–85. doi:10.1097/ADM.0b013e3181c82207.
   PubMed Web of Science ®Google Scholar
• Donoghue, K., C. Elzerbi, R. Saunders, C. Whittington, S. Pilling, and C. Drummond. 2015. The efficacy of Acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: A meta-analysis. Addiction (Abingdon, England) 110 (6):920–30. doi:10.1111/add.12875.
   PubMed Web of Science ®Google Scholar
• Edelman, E. J., B. A. Moore, S. R. Holt, N. Hansen, T. C. Kyriakides, M. Virata, S. T. Brown, A. C. Justice, K. J. Bryant, D. A. Fiellin, et al. 2019. Efficacy of extended-release naltrexone on HIV-related and drinking outcomes among HIV-positive patients: A randomized-controlled trial. AIDS and Behavior 23 (1):211–21. doi:10.1007/s10461-018-2241-z.
   PubMed Web of Science ®Google Scholar
• Farhadian, N., S. Moradi, M. H. Zamanian, V. Farnia, S. Rezaeian, M. Farhadian, and M. Shahlaei. 2020. Effectiveness of naltrexone treatment for alcohol use disorders in HIV: A systematic review. Substance Abuse Treatment, Prevention, and Policy 15 (1). doi:10.1186/s13011-020-00266-6.
   PubMed Web of Science ®Google Scholar
• Flanagan, J. C., J. L. Jones, A. M. Jarnecke, and S. E. Back. 2018. Behavioral treatments for alcohol use disorder and post-traumatic stress disorder. Alcohol Research : Current Reviews 39 (2):181–92.
   PubMed Web of Science ®Google Scholar
• Garbutt, J. C. 2009. The state of pharmacotherapy for the treatment of alcohol dependence. Journal of Substance Abuse Treatment 36 (1):S15-23; quiz S24–25.
   Web of Science ®Google Scholar
• Garbutt, J. C., H. R. Kranzler, S. S. O’Malley, D. R. Gastfriend, H. M. Pettinati, B. L. Silverman, J. W. Loewy, and E. W. Ehrich; Vivitrex Study Group. 2005. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 293 (13):1617–25. doi:10.1001/jama.293.13.1617.
   PubMed Web of Science ®Google Scholar
• GBD 2016 Alcohol and Drug Use Collaborators. 2018. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet. Psychiatry 5 (12):987–1012. doi:10.1016/S2215-0366(18)30337-7.
   PubMed Web of Science ®Google Scholar
• Gianoulakis, C. 1996. Implications of endogenous opioids and dopamine in alcoholism: Human and basic science studies. Alcohol and Alcoholism (Oxford, Oxfordshire) 31 Suppl 1:33–42. doi:10.1093/oxfordjournals.alcalc.a008216.
   PubMed Web of Science ®Google Scholar
• Herz, A. 1997. Endogenous opioid systems and alcohol addiction. Psychopharmacology 129 (2):99–111. doi:10.1007/s002130050169.
   PubMed Web of Science ®Google Scholar
• Higgins, J., and S. Green. 2011. Cochrane handbook for systematic reviews of interventions. Chichester (UK): John Wiley & Sons.
   Google Scholar
• Hulse, G. K. 2013. Improving clinical outcomes for naltrexone as a management of problem alcohol use. British Journal of Clinical Pharmacology 76 (5):632–41. doi:10.1111/j.1365-2125.2012.04452.x.
   PubMed Web of Science ®Google Scholar
• Jarosz, J., K. Miernik, M. Wąchal, J. Walczak, and G. Krumpl. 2013. Naltrexone (50 Mg) plus psychotherapy in alcohol-dependent patients: A meta-analysis of randomized controlled trials. The American Journal of Drug and Alcohol Abuse 39 (3):144–60. doi:10.3109/00952990.2013.796961.
   PubMed Web of Science ®Google Scholar
• Johnson, B. A., N. Ait-Daoud, H.-J. Aubin, W. Van Den Brink, R. Guzzetta, J. Loewy, B. Silverman, and E. Ehrich. 2004. A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence. Alcoholism, Clinical and Experimental Research 28 (9):1356–61. doi:10.1097/01.ALC.0000139823.30096.52.
   PubMed Web of Science ®Google Scholar
• Jonas, D. E., H. R. Amick, C. Feltner, G. Bobashev, K. Thomas, R. Wines, M. M. Kim, E. Shanahan, C. E. Gass, C. J. Rowe, et al. 2014. Pharmacotherapy for adults with alcohol use disorders in outpatient settings: A systematic review and meta-analysis. JAMA 311 (18):1889–900. doi:10.1001/jama.2014.3628.
   PubMed Web of Science ®Google Scholar
• Kim, Y., L. Hack, E. S. Ahn, and J. Kim. 2018. Practical outpatient pharmacotherapy for alcohol use disorder. Drugs in Context 7:1–14. doi:10.7573/dic.212308.
   Google Scholar
• Korthuis, P. T., P. J. Lum, P. Vergara‐Rodriguez, K. Ahamad, E. Wood, L. E. Kunkel, N. L. Oden, R. Lindblad, J. L. Sorensen, V. Arenas, et al.; for the CTN‐0055 CHOICES Investigators. 2017. Feasibility and safety of extended‐release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: A pilot/feasibility randomized trial. Addiction. 112 (6):1036–44. doi:10.1111/add.13753.
   PubMed Web of Science ®Google Scholar
• Kranzler, H. R., D. R. Wesson, and L. Billot. 2004. Naltrexone depot for treatment of alcohol dependence: A multicenter, randomized, placebo-controlled clinical trial. Alcoholism, Clinical and Experimental Research 28 (7):1051–59. doi:10.1097/01.ALC.0000130804.08397.29.
   PubMed Web of Science ®Google Scholar
• Lee, J. D., E. Grossman, D. DiRocco, A. Truncali, K. Hanley, D. Stevens, J. Rotrosen, and M. N. Gourevitch. 2010. Extended-release naltrexone for treatment of alcohol dependence in primary care. Journal of Substance Abuse Treatment 39 (1):14–21. doi:10.1016/j.jsat.2010.03.005.
   PubMed Web of Science ®Google Scholar
• Lee, J. D., E. Grossman, L. Huben, M. Manseau, J. McNeely, J. Rotrosen, D. Stevens, and M. N. Gourevitch. 2012. Extended-release naltrexone plus medical management alcohol treatment in primary care: Findings at 15 months. Journal of Substance Abuse Treatment 43 (4):458–62. doi:10.1016/j.jsat.2012.08.012.
   PubMed Web of Science ®Google Scholar
• Lobmaier, P., H. Kornør, N. Kunøe, and A. Bjørndal. 2008. Sustained-release naltrexone for opioid dependence. The Cochrane Database of Systematic Reviews 2:CD006140. doi:10.1002/14651858.CD006140.pub2.
   Google Scholar
• Lobmaier, P., N. Kunøe, M. Gossop, and H. Waal. 2011. Naltrexone depot formulations for opioid and alcohol dependence: A systematic review. CNS Neuroscience & Therapeutics 17 (6):629–36. doi:10.1111/j.1755-5949.2010.00194.x.
   PubMed Web of Science ®Google Scholar
• Longabaugh, R., P. W. Wirtz, S. B. Gulliver, and D. Davidson. 2009. Extended naltrexone and broad spectrum treatment or motivational enhancement therapy. Psychopharmacology 206 (3):367–76. doi:10.1007/s00213-009-1615-3.
   PubMed Web of Science ®Google Scholar
• Mannelli, P., K. Peindl, P. S. Masand, and A. A. Patkar. 2007. Long-acting injectable naltrexone for the treatment of alcohol dependence. Expert Review of Neurotherapeutics 7 (10):1265–77. doi:10.1586/14737175.7.10.1265.
   PubMedGoogle Scholar
• Moher, D., L. Shamseer, M. Clarke, D. Ghersi, A. Liberati, M. Petticrew, P. Shekelle, and L. A. Stewart. 2015. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews 4 (1):1. doi:10.1186/2046-4053-4-1.
   PubMed Web of Science ®Google Scholar
• National Institute on Alcohol Abuse and Alcoholism. 2018. Alcohol facts and statistics. National Institute on Alcohol Abuse and Alcoholism (NIAAA). https://www.niaaa.nih.gov/alcohol-health/overview-alcohol-consumption/alcohol-facts-and-statistics (Accessed August 05, 2019).
   Google Scholar
• NIH. 2019. Alcohol Facts and Statistics. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/alcohol-facts-and-statistics ( Accessed 05.05.2022).
   Google Scholar
• O’Malley, S. S., J. C. Garbutt, D. R. Gastfriend, Q. Dong, and H. R. Kranzler. 2007. Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. Journal of Clinical Psychopharmacology 27 (5):507–12. doi:10.1097/jcp.0b013e31814ce50d.
   PubMed Web of Science ®Google Scholar
• Pettinati, H. M., D. R. Gastfriend, Q. Dong, H. R. Kranzler, and S. S. O’Malley. 2009. Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcoholism, Clinical and Experimental Research 33 (2):350–56. doi:10.1111/j.1530-0277.2008.00843.x.
   PubMed Web of Science ®Google Scholar
• Pettinati, H. M., B. L. Silverman, J. J. Battisti, R. Forman, E. Schweizer, and D. R. Gastfriend. 2011. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcoholism, Clinical and Experimental Research 35 (10):1804–11. doi:10.1111/j.1530-0277.2011.01524.x.
   PubMed Web of Science ®Google Scholar
• Ray, L. A., S. Bujarski, E. Grodin, E. Hartwell, R. Green, A. Venegas, A. C. Lim, A. Gillis, and K. Miotto. 2019. State-of-the-art behavioral and pharmacological treatments for alcohol use disorder. The American Journal of Drug and Alcohol Abuse 45 (2):124–40. doi:10.1080/00952990.2018.1528265.
   PubMed Web of Science ®Google Scholar
• Ray, L. A., L. R. Meredith, B. D. Kiluk, J. Walthers, K. M. Carroll, and M. Magill. 2020. Combined pharmacotherapy and cognitive behavioral therapy for adults with alcohol or substance use disorders: A systematic review and meta-analysis. JAMA Network Open 3 (6):e208279. doi:10.1001/jamanetworkopen.2020.8279.
   PubMed Web of Science ®Google Scholar
• Rehm, J., and K. D. Shield. 2019. Global burden of alcohol use disorders and alcohol liver disease. Biomedicines 7 (4):99. doi:10.3390/biomedicines7040099.
   PubMed Web of Science ®Google Scholar
• Roozen, H. G., R. de Waart, and W. van den Brink. 2007. Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: Oral versus injectable delivery. European Addiction Research 13 (4):201–06. doi:10.1159/000104882.
   PubMed Web of Science ®Google Scholar
• Roozen, H. G., R. de Waart, D. A. W. M. van der Windt, W. van den Brink, C. A. J. de Jong, and A. J. F. M. Kerkhof. 2006. A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 16 (5):311–23. doi:10.1016/j.euroneuro.2005.11.001.
   PubMed Web of Science ®Google Scholar
• Sawicka, M., and D. K. Tracy. 2017. Naltrexone efficacy in treating alcohol-use disorder in individuals with comorbid psychosis: A systematic review. Therapeutic Advances in Psychopharmacology 7 (8–9):211–24. doi:10.1177/2045125317709975.
   PubMed Web of Science ®Google Scholar
• Springer, S. A., A. Di Paola, M. M. Azar, R. Barbour, A. Krishnan, and F. L. Altice. 2017. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug and Alcohol Dependence 174:158–70. doi:10.1016/j.drugalcdep.2017.01.026.
   PubMed Web of Science ®Google Scholar
• Swiatek, D., N. A. Bosso, and L. P. Hughes. 2018. Naltrexone for the treatment of alcohol use disorder in the primary care setting. US Pharm 43 (26–33):9.
   Google Scholar
• Swift, R., D. W. Oslin, M. Alexander, and R. Forman. 2011. Adherence monitoring in naltrexone pharmacotherapy trials: A systematic review. Journal of Studies on Alcohol and Drugs 72 (6):1012–18. doi:10.15288/jsad.2011.72.1012.
   PubMed Web of Science ®Google Scholar
• Swift, R. M., W. Whelihan, O. Kuznetsov, G. Buongiorno, and H. Hsuing. 1994. Naltrexone-induced alterations in human ethanol intoxication. The American Journal of Psychiatry 151 (10):1463–67. doi:10.1176/ajp.151.10.1463.
   PubMed Web of Science ®Google Scholar
• Vinson, D. C., B. K. Manning, J. M. Galliher, L. M. Dickinson, W. D. Pace, and B. J. Turner. 2010. Alcohol and sleep problems in primary care patients: A report from the AAFP National Research Network. The Annals of Family Medicine 8 (6):484–92. doi:10.1370/afm.1175.
   PubMed Web of Science ®Google Scholar
• Watkins, K. E., A. J. Ober, K. Lamp, M. Lind, C. Setodji, K. C. Osilla, S. B. Hunter, C. M. McCullough, K. Becker, P. O. Iyiewuare, et al. 2017. Collaborative care for opioid and alcohol use disorders in primary care: The SUMMIT randomized clinical trial. JAMA Internal Medicine 177 (10):1480–88. doi:10.1001/jamainternmed.2017.3947.
   PubMed Web of Science ®Google Scholar
• Winslow, B. T., and M. Onysko. 2016. Medications for alcohol use disorder. American Family Physician 93 (6):457–65.
   PubMed Web of Science ®Google Scholar
• World Health Organization. 2019. Global status report on alcohol and health 2018. WHO. http://www.who.int/substance_abuse/publications/global_alcohol_report/en/ (Accessed August 05, 2019).
   Google Scholar